<h2 data-section-id="gnw565" data-start="0" data-end="45"><strong>Alzheimer&rsquo;s Disease Market</strong></h2>
<p data-start="47" data-end="508">The <a href="https://www.delveinsight.com/report-store/alzheimers-disease-ad-market"><strong>Alzheimer&rsquo;s disease market</strong></a> across the 7MM reached nearly USD 4 billion in 2025, driven by the launch of innovative disease-modifying therapies, improved diagnostic technologies, and rising disease awareness. The US accounted for nearly 50% of the total market share, followed by EU4 and the UK with 30%, and Japan with 20%. The market is projected to grow at a CAGR of 22.7% during 2026-2036 due to increasing diagnosis rates and expanding treatment access.</p>
<h3 data-start="510" data-end="535"><strong data-start="510" data-end="535">Key Market Highlights</strong></h3>
<ul data-start="536" data-end="777">
<li data-section-id="o359x1" data-start="536" data-end="583">7MM market size reached USD 4 billion in 2025</li>
<li data-section-id="1wrjycy" data-start="584" data-end="654">Disease-modifying therapies are expected to dominate future revenues</li>
<li data-section-id="12ovskg" data-start="655" data-end="719">Improved biomarker testing and imaging support early diagnosis</li>
<li data-section-id="sooa5n" data-start="720" data-end="777">Aging populations continue to expand the treatment pool</li>
</ul>
<h3 data-start="779" data-end="797"><strong data-start="779" data-end="797">Approved Drugs</strong></h3>
<ul data-start="798" data-end="1027">
<li data-section-id="1qy7add" data-start="798" data-end="847"><span class="whitespace-normal">Eli Lilly and Company</span> - KISUNLA</li>
<li data-section-id="1f36v5b" data-start="848" data-end="937"><span class="whitespace-normal">Biogen</span> / <span class="whitespace-normal">Eisai</span> - <a href="https://www.delveinsight.com/report-store/leqembi-market-size-forecast-and-market-insight"><strong>LEQEMBI</strong></a></li>
<li data-section-id="3w5n9b" data-start="938" data-end="1027"><span class="whitespace-normal">Otsuka Pharmaceutical</span> / <span class="whitespace-normal">Lundbeck</span> - <a href="https://www.delveinsight.com/report-store/rexulti-and-zoloft-combination-emerging-drug-insight-and-market-forecast"><strong>REXULTI</strong></a></li>
</ul>
<h2 data-section-id="uk04xj" data-start="1034" data-end="1076"><strong>Alzheimer&rsquo;s Disease Epidemiology</strong></h2>
<p data-start="1078" data-end="1569"><a href="https://www.delveinsight.com/report-store/alzheimers-disease-ad-epidemiology-forecast"><strong>Alzheimer&rsquo;s disease</strong></a> remains one of the most prevalent neurodegenerative disorders globally, with nearly 15 million diagnosed prevalent cases across the 7MM in 2025. The disease burden is highest in the US, contributing 44% of total diagnosed cases, while EU4 and the UK accounted for 31%, and Japan represented 25%. Increasing life expectancy and improved diagnostic approaches, including <a href="https://www.delveinsight.com/report-store/magnetic-resonance-imaging-devices-market"><strong>MRI</strong></a>, <a href="https://www.delveinsight.com/report-store/carotid-stenotic-scan-devices-market"><strong>CT scans</strong></a>, laboratory testing, and biomarker assessments, continue to enhance case identification.</p>
<h3 data-start="1571" data-end="1600"><strong data-start="1571" data-end="1600">Epidemiology Segmentation</strong></h3>
<ul data-start="1601" data-end="1809">
<li data-section-id="z9lw5h" data-start="1601" data-end="1634">Gender-specific diagnosed cases</li>
<li data-section-id="1jcqihl" data-start="1635" data-end="1665">Age-specific diagnosed cases</li>
<li data-section-id="wpczzd" data-start="1666" data-end="1701">Severity-specific diagnosed cases</li>
<li data-section-id="z2lq75" data-start="1702" data-end="1737">Genotype-specific diagnosed cases</li>
<li data-section-id="tfprk" data-start="1738" data-end="1768">Confirmed A&beta; pathology cases</li>
<li data-section-id="15n07wb" data-start="1769" data-end="1809">Treated Alzheimer&rsquo;s disease population</li>
</ul>
<h3 data-start="1811" data-end="1840"><strong data-start="1811" data-end="1840">Key Epidemiology Insights</strong></h3>
<ul data-start="1841" data-end="2111">
<li data-section-id="veiiy5" data-start="1841" data-end="1897">Total diagnosed prevalent cases in the 7MM: 15 million</li>
<li data-section-id="1w3j43j" data-start="1898" data-end="1979">The US reported nearly 5 million agitation-associated Alzheimer&rsquo;s disease cases</li>
<li data-section-id="wieku1" data-start="1980" data-end="2037">Rising cognitive screening is improving diagnosis rates</li>
<li data-section-id="14nnpp6" data-start="2038" data-end="2111">Early-stage and preclinical Alzheimer&rsquo;s disease detection is increasing</li>
</ul>
<h2 data-section-id="ebd8al" data-start="2118" data-end="2166"><strong>Alzheimer&rsquo;s Disease Pipeline</strong></h2>
<p data-start="2168" data-end="2595">The Alzheimer&rsquo;s disease pipeline is rapidly evolving with multiple companies developing therapies targeting amyloid beta, neuroinflammation, kinase inhibition, and metabolic dysfunction. Several late-stage candidates are focused on slowing cognitive decline and improving long-term disease management. The emergence of oral agents and subcutaneous formulations is also improving patient convenience and treatment accessibility.</p>
<h3 data-start="2597" data-end="2615"><strong data-start="2597" data-end="2615">Emerging Drugs</strong></h3>
<ul data-start="2616" data-end="2925">
<li data-section-id="cab5t4" data-start="2616" data-end="2667"><a href="https://www.delveinsight.com/report-store/masitinib-emerging-drug-insight-and-market-forecast"><strong>Masitinib</strong></a> - <span class="whitespace-normal">AB Science</span></li>
<li data-section-id="18ek3ol" data-start="2668" data-end="2717"><a href="https://www.delveinsight.com/report-store/alz-801-market-size-forecast-and-emerging-insight"><strong>ALZ-801</strong></a> - <span class="whitespace-normal">Alzheon</span></li>
<li data-section-id="fc3y9h" data-start="2718" data-end="2766"><a href="https://www.delveinsight.com/report-store/ar1001-market-size-forecast-and-emerging-insight"><strong>AR1001</strong></a> - <span class="whitespace-normal">AriBio</span></li>
<li data-section-id="hw719k" data-start="2767" data-end="2815"><a href="https://www.delveinsight.com/report-store/ne3107-market-size-forecast-and-emerging-insight"><strong>NE3107</strong></a> - <span class="whitespace-normal">BioVie</span></li>
<li data-section-id="s83a1e" data-start="2816" data-end="2869"><a href="https://www.delveinsight.com/report-store/remternetug-market-size-forecast-and-emerging-insight"><strong>Remternetug</strong></a> - <span class="whitespace-normal">Eli Lilly and Company</span></li>
<li data-section-id="b0x73y" data-start="2870" data-end="2925"><a href="https://www.delveinsight.com/report-store/semaglutide-market-size-forecast-and-emerging-insight"><strong>Semaglutide</strong></a> - <span class="whitespace-normal">Novo Nordisk</span></li>
</ul>
<h3 data-start="2927" data-end="2946"><strong data-start="2927" data-end="2946">Pipeline Trends</strong></h3>
<ul data-start="2947" data-end="3174" data-is-last-node="" data-is-only-node="">
<li data-section-id="1ou3j5u" data-start="2947" data-end="2992">Strong focus on disease-modifying therapies</li>
<li data-section-id="18iu4rn" data-start="2993" data-end="3064">Increased investment in anti-amyloid and anti-inflammatory approaches</li>
<li data-section-id="o2vfz4" data-start="3065" data-end="3116">Expansion of oral and self-administered therapies</li>
<li data-section-id="1hssjmv" data-start="3117" data-end="3174" data-is-last-node="">Growing research collaborations accelerating innovation</li>
</ul>

Alzheimer's Disease Market

Alzheimer's Disease Infographics

Alzheimer’s Disease Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape